EP300 and small cell lung carcinoma: Together, this suggests that an ERK-MSK/RSK-CBP/p300-ETS axis, acting through multiple points, synergizes to suppress NE differentiation, providing biological rationale for the absence of MAPK pathway activation in SCLC (Figure 7a).